Q: What is Aimovig used for?

Aimovig is used to treat migraine prevention .

Q: How does Aimovig work?

Mechanism of Action Aimovig belongs to a class of drugs known as calcitonin gene-related peptide (CGRP) receptor antagonists. It is a monoclonal antibody, which is a type of protein designed to recognize and attach to a specific target in the body. Research suggests that a protein called CGRP plays a central role in migraine attacks. During a migraine, CGRP levels often increase, leading to several biological changes, including: Dilation (widening) of blood vessels in the brain. Inflammation of the surrounding tissues. Transmission of pain signals through the nervous system. Aimovig works by binding directly to the CGRP receptors located on the surface of cells. By occupying these receptors, the medication prevents the CGRP protein from attaching to them. This action blocks the protein's ability to trigger the cascade of events that result in migraine pain and other symptoms, thereby helping to reduce the frequency of migraine days.

Q: What are the active ingredients in Aimovig?

The active ingredient in Aimovig is erenumab .

Q: What are the side effects of Aimovig?

Common side effects of Aimovig may include: injection site reactions constipation muscle cramps Always consult with a healthcare professional about potential side effects.

Q: What drug class is Aimovig?

Aimovig belongs to the CGRP receptor antagonist drug class.

Q: What is the dosage of Aimovig and how do I take it?

How to Use Aimovig Aimovig is given as an injection under the skin (subcutaneously) once a month. You or a caregiver can be trained to administer the injection at home using a prefilled autoinjector or syringe. Injection Sites Common areas for injection include: The abdomen (avoiding the area around the belly button). The front of the thighs. The outer area of the upper arm (only if someone else is giving the injection). It is important to rotate injection sites and avoid areas where the skin is tender, bruised, red, or hard. Preparation Before injecting, remove the medication from the refrigerator and allow it to reach room temperature naturally. Do not heat the medication or leave it in direct sunlight. Do not shake the device. Before use, check the liquid through the viewing window; it should be clear or pale yellow. Do not use the medication if it looks cloudy, discolored, or contains large particles. Missed Dose If you miss a dose of Aimovig, take it as soon as you remember. Your next dose should then be scheduled for one month after the date of that injection. Do not take two doses at the same time to make up for a missed one.

Q: Is Aimovig safe during pregnancy and breastfeeding?

Pregnancy There is currently limited data on the use of Aimovig in pregnant women to determine if there is a risk of birth defects or miscarriage. Animal studies conducted on monkeys did not show evidence of harm to the fetus, even at doses much higher than those used in humans. However, because Aimovig is a monoclonal antibody, it may be transferred from the mother to the fetus during pregnancy. If you are pregnant or planning to become pregnant, your healthcare provider can help you decide if the benefits of migraine prevention outweigh the potential risks. There may also be pregnancy registries available to monitor the health of individuals who use this medication during pregnancy. Breastfeeding It is unknown whether Aimovig passes into human breast milk or if it has any effect on a nursing infant or milk production. While many large protein medications are present in breast milk, they are often broken down in the infant's stomach. You should consult with a healthcare professional to determine the best course of action while breastfeeding.

Q: What is the FDA approval status of Aimovig?

FDA Approval and Indication The U.S. Food and Drug Administration (FDA) approved Aimovig (erenumab-aooe) in May 2018. It is indicated for the preventive treatment of migraine in adults. It was the first medication in the class of calcitonin gene-related peptide (CGRP) receptor antagonists to be approved for migraine prevention. Safety Communications The FDA monitors the safety of medications after they are approved through the FDA Adverse Event Reporting System (FAERS). Based on post-marketing reports, the FDA has identified and addressed specific safety concerns: Hypertension: In 2019, the FDA identified a potential signal of serious risk for high blood pressure (hypertension) or the worsening of existing high blood pressure. The prescribing information was updated to include these risks. Severe Constipation: In 2020, the FDA identified a potential signal for constipation with serious complications. The drug's labeling was updated to reflect that some cases of constipation have led to hospitalization or surgery. Aimovig is not currently subject to a boxed warning or a Risk Evaluation and Mitigation Strategy (REMS) program.

Question 1

What is Aimovig?

Accepted Answer

Aimovig belongs to a class of drugs known as calcitonin gene-related peptide (CGRP) receptor antagonists. It is a monoclonal antibody designed to target and block the activity of a specific protein in the body that is associated with the development of migraine attacks.

By binding to these receptors, the medication helps to reduce the frequency of migraine episodes. This therapy represents a targeted approach to migraine management by interfering with the biological pathways that contribute to head pain.

Question 2

What is Aimovig used for?

Accepted Answer

Aimovig is used to treat migraine prevention.

Question 3

How does Aimovig work?

Accepted Answer

Mechanism of Action

Aimovig belongs to a class of drugs known as calcitonin gene-related peptide (CGRP) receptor antagonists. It is a monoclonal antibody, which is a type of protein designed to recognize and attach to a specific target in the body.

Research suggests that a protein called CGRP plays a central role in migraine attacks. During a migraine, CGRP levels often increase, leading to several biological changes, including:

Dilation (widening) of blood vessels in the brain.
Inflammation of the surrounding tissues.
Transmission of pain signals through the nervous system.

Aimovig works by binding directly to the CGRP receptors located on the surface of cells. By occupying these receptors, the medication prevents the CGRP protein from attaching to them. This action blocks the protein's ability to trigger the cascade of events that result in migraine pain and other symptoms, thereby helping to reduce the frequency of migraine days.

Question 4

What are the active ingredients in Aimovig?

Accepted Answer

The active ingredient in Aimovig is erenumab.

Question 5

What are the side effects of Aimovig?

Accepted Answer

Common side effects of Aimovig may include:

injection site reactions
constipation
muscle cramps

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Aimovig?

Accepted Answer

Aimovig belongs to the CGRP receptor antagonist drug class.

Question 7

What is the dosage of Aimovig and how do I take it?

Accepted Answer

How to Use Aimovig

Aimovig is given as an injection under the skin (subcutaneously) once a month. You or a caregiver can be trained to administer the injection at home using a prefilled autoinjector or syringe.

Injection Sites

Common areas for injection include:

The abdomen (avoiding the area around the belly button).
The front of the thighs.
The outer area of the upper arm (only if someone else is giving the injection).

It is important to rotate injection sites and avoid areas where the skin is tender, bruised, red, or hard.

Preparation

Before injecting, remove the medication from the refrigerator and allow it to reach room temperature naturally. Do not heat the medication or leave it in direct sunlight. Do not shake the device. Before use, check the liquid through the viewing window; it should be clear or pale yellow. Do not use the medication if it looks cloudy, discolored, or contains large particles.

Missed Dose

If you miss a dose of Aimovig, take it as soon as you remember. Your next dose should then be scheduled for one month after the date of that injection. Do not take two doses at the same time to make up for a missed one.

Question 8

Is Aimovig safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

There is currently limited data on the use of Aimovig in pregnant women to determine if there is a risk of birth defects or miscarriage. Animal studies conducted on monkeys did not show evidence of harm to the fetus, even at doses much higher than those used in humans. However, because Aimovig is a monoclonal antibody, it may be transferred from the mother to the fetus during pregnancy.

If you are pregnant or planning to become pregnant, your healthcare provider can help you decide if the benefits of migraine prevention outweigh the potential risks. There may also be pregnancy registries available to monitor the health of individuals who use this medication during pregnancy.

Breastfeeding

It is unknown whether Aimovig passes into human breast milk or if it has any effect on a nursing infant or milk production. While many large protein medications are present in breast milk, they are often broken down in the infant's stomach. You should consult with a healthcare professional to determine the best course of action while breastfeeding.

Question 9

What forms and strengths does Aimovig come in?

Accepted Answer

Aimovig is available as a liquid solution for subcutaneous injection. It is supplied in the following delivery formats:

Prefilled Autoinjector
Prefilled Syringe

These devices are intended for administration into the thigh, abdomen, or upper arm.

Question 10

What is the FDA approval status of Aimovig?

Accepted Answer

FDA Approval and Indication

The U.S. Food and Drug Administration (FDA) approved Aimovig (erenumab-aooe) in May 2018. It is indicated for the preventive treatment of migraine in adults. It was the first medication in the class of calcitonin gene-related peptide (CGRP) receptor antagonists to be approved for migraine prevention.

Safety Communications

The FDA monitors the safety of medications after they are approved through the FDA Adverse Event Reporting System (FAERS). Based on post-marketing reports, the FDA has identified and addressed specific safety concerns:

Hypertension: In 2019, the FDA identified a potential signal of serious risk for high blood pressure (hypertension) or the worsening of existing high blood pressure. The prescribing information was updated to include these risks.
Severe Constipation: In 2020, the FDA identified a potential signal for constipation with serious complications. The drug's labeling was updated to reflect that some cases of constipation have led to hospitalization or surgery.

Aimovig is not currently subject to a boxed warning or a Risk Evaluation and Mitigation Strategy (REMS) program.

Question 11

What should I know about Aimovig and cost?

Accepted Answer

Insurance Coverage

Most insurance plans cover Aimovig, but they often require prior authorization. This is a process where your doctor must confirm the medication is medically necessary before the insurance company agrees to pay for it. Your specific out-of-pocket cost will depend on your plan's deductible and copayment tiers.

Financial Assistance Options

Because Aimovig is a brand-name medication without a generic alternative, there are programs designed to help manage the cost:

Copay Cards: Patients with commercial insurance may qualify for savings cards that reduce monthly costs.
Patient Assistance Programs: These programs may provide the medication at no cost to individuals who meet specific income requirements and lack insurance coverage.

Medicare and Medicaid

Coverage for Aimovig under Medicare and Medicaid varies by plan and state. While patients with government insurance are generally not eligible for manufacturer copay cards, they may qualify for other forms of financial support, such as the Extra Help program for Medicare Part D.

Aimovig

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Aimovig

Hospitals.net Disclosure